Fibrinogen

What it actually measures

Fibrinogen is a large protein your liver makes, and its job is the last step of clotting.

When a clot forms, an enzyme called thrombin converts soluble fibrinogen into insoluble fibrin, which forms the mesh that holds a clot together. Without fibrinogen you cannot form a stable clot at all.

So it is a clotting factor, and that is its primary and non-negotiable function.

It is also an acute phase reactant. During an inflammatory response, your liver increases fibrinogen production along with C-reactive protein and others, which means fibrinogen rises with inflammation of any kind.

That dual identity is what makes it interesting as a marker. A raised fibrinogen means more clotting capacity and more inflammation at the same time, and both of those are relevant to cardiovascular risk.

It also increases blood viscosity, which is a third mechanism by which it plausibly contributes rather than merely reporting.

What the largest dataset actually shows

The evidence base here is unusually large, and it is worth stating the size because it is what gives the finding its weight.

A 2005 individual participant meta-analysis published in JAMA pooled data on 154,211 participants across 31 prospective studies, covering 1.38 million person-years, with 6,944 first non-fatal heart attacks or strokes and 13,210 deaths.

Individual participant data means the researchers had each person's records rather than only published summaries, which allows far better adjustment and is a considerably stronger design than a conventional meta-analysis.

It found an approximately log-linear association between usual plasma fibrinogen and coronary heart disease, stroke, other vascular mortality and non-vascular mortality, with no threshold below which risk stopped falling.

Per 1 g/L increase in usual fibrinogen: coronary heart disease at a hazard ratio of 2.42, stroke at 2.06, other vascular mortality at 2.76, and non-vascular mortality at 2.03.

Those look enormous, and the honest reading requires the next sentence. After adjustment for established cardiovascular risk factors, the hazard ratios fell to around 1.8, which is still substantial and considerably less dramatic than the unadjusted figures.

Two further findings matter. The coronary association was essentially unchanged after adjusting for C-reactive protein in a subset of 7,011 people, which suggests fibrinogen carries information beyond what CRP already tells you.

And the association with non-vascular mortality is a genuine puzzle. A marker that predicts death from causes unrelated to blood vessels is probably reflecting general illness burden as well as vascular risk, and that complicates any simple causal story.

What moves it

Down: stopping smoking, which is one of the more reliable levers. Regular physical activity. Losing excess weight. Treating whatever inflammatory process is driving it. Moderate alcohol is associated with lower levels, which is a correlation rather than a recommendation. Some medications lower it, and that is a prescribing matter.

Up: inflammation of any kind, including infection, injury and autoimmune disease. Smoking, substantially. Excess body weight. Pregnancy and oestrogen including oral contraceptives. Increasing age. Diabetes. And genetics, which accounts for a meaningful share of the variation between people.

The honest hedge

I am not a doctor and I am not diagnosing anyone.

The honest limitation here is the same one that applies to every observational cardiovascular marker: an association, however large the dataset, is not proof that lowering the marker helps.

Fibrinogen is a good illustration of why that matters. It rises with inflammation, with smoking, with excess weight and with age, all of which independently affect cardiovascular risk. Disentangling how much fibrinogen contributes itself from how much it simply reports on those is genuinely difficult.

The non-vascular mortality association is the clearest signal of that problem. Something predicting death from causes unrelated to blood vessels is reflecting general illness burden alongside anything vascular.

So I would treat a raised fibrinogen as a prompt to look at what is driving it rather than as a target to lower directly.

There is also a clinical direction people forget. Low fibrinogen matters too, and a genuinely low value affects clotting and belongs with a doctor rather than being celebrated.

Practically, fibrinogen is not on a standard panel, and for most people building a cardiovascular picture, apoB and hs-CRP are better first calls.

So. What to actually do.

Tonight, at no cost. If smoking is on your list, that is the single largest lever on this marker and on nearly everything else in this section.

Build the cheaper picture first. ApoB and hs-CRP answer more per pound for most people than fibrinogen does.

If it is raised, ask what is driving it. Inflammation, smoking, weight and age all raise it, and those are where the actionable answers live.

Read it alongside CRP rather than instead of it. The meta-analysis found the coronary association essentially unchanged after CRP adjustment, which means they carry different information.

Do not chase the number in isolation. The association with non-vascular mortality suggests it partly reports general illness burden rather than a single mechanism.

Take a genuinely low value to a doctor. Low fibrinogen affects clotting and is a finding rather than a win.

Work the levers that move it and everything else. Not smoking, movement, weight, and treating active inflammation.

You are not a clotting protein. You are a system where the same molecule seals a wound and reports a fire, which is why it predicts so much and explains so little on its own.

Your body is not broken. It is blocked. And a raised fibrinogen is usually pointing at the block rather than being it.

Go look at what would be driving it.